NGM·Healthcare·$541M·#158 / 520 in Healthcare
NPCE Neuropace, Inc.
57SPECULATIVE
CATEGORY BREAKDOWN
GROWTH40
QUALITY73
STABILITY56
VALUATION68
GOVERNANCE49
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+25.1%
40
> 50% strong
Gross Margin
Revenue retained after direct costs
77.2%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
24 months
84
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
372.2%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
5.4x
68
< 3x strong
Rule of 40
Growth rate plus operating margin
9
33
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.0%
32
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+3.2%
81
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE NPCE WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when NPCE's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.